ALNY vs. SMMT: Alnylam Pharmaceuticals vs. Summit Therapeutics Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ALNY | SMMT |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| Total Return (1Y) | -64.57% | -2.48% |
| Total Return (3Y, Annualized) | -1.58% | 116.18% |
| Total Return (5Y, Annualized) | -3.13% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Alnylam Pharmaceuticals (ALNY) has a non-negative beta of 0.45.
| Metric | ALNY | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 75.06% |
| Beta (5Y) | 0.45 | -1.51 |
| Max Drawdown (5Y) | -68.25% | -87.64% |
| Avg. Volume (3M) | 1.90M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | -0.09 |
| Sortino Ratio (1Y) | -1.45 | -0.13 |
Profitability
ROE (TTM)
Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 52.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| ROE (TTM) | 138.07% | -220.01% |
| ROA (TTM) | 9.51% | -111.99% |
| Net Margin (TTM) | 52.85% | 0.00% |
| Operating Margin (TTM) | 23.72% | 0.00% |
| Gross Margin (TTM) | 77.28% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Alnylam Pharmaceuticals (ALNY) reports revenue growth of 65.19%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Neither Alnylam Pharmaceuticals (ALNY) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | -- |
| Revenue Growth (3Y CAGR) | 52.98% | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 5.99 |
| Debt / Equity (MRQ) | 0.83 | 0.04 |
| Net Debt / EBITDA | -0.57 | -- |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Alnylam Pharmaceuticals (ALNY), whose P/S ratio of 4.17 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | SMMT |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | -- |
| P/S Ratio (TTM) | 4.17 | -- |
| P/B Ratio (MRQ) | 5.79 | 23.13 |
| Free Cash Flow Yield (TTM) | 1.57% | -1.64% |